奥翔药业
(603229)
| 流通市值：67.17亿 | | | 总市值：67.17亿 |
| 流通股本：8.30亿 | | | 总股本：8.30亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 306,636,220.57 | 795,288,308.9 | 690,126,439.62 | 492,393,814.37 |
| 营业收入 | 306,636,220.57 | 795,288,308.9 | 690,126,439.62 | 492,393,814.37 |
| 二、营业总成本 | 169,849,438.7 | 575,480,342.93 | 436,562,072.07 | 282,548,002.93 |
| 营业成本 | 119,555,628.58 | 363,980,823.63 | 290,269,738.53 | 197,918,579.17 |
| 税金及附加 | 1,512,984.6 | 11,453,544.14 | 6,112,941.91 | 4,506,069.57 |
| 销售费用 | 3,315,967.99 | 16,754,363.21 | 9,841,817.53 | 7,049,149.72 |
| 管理费用 | 20,819,884.92 | 106,450,831.01 | 70,882,567.65 | 46,217,951.22 |
| 研发费用 | 28,303,999.3 | 100,419,204.52 | 64,018,512.4 | 40,416,045.22 |
| 财务费用 | -3,659,026.69 | -23,578,423.58 | -4,563,505.95 | -13,559,791.97 |
| 其中:利息费用 | 1,699,456.85 | 7,764,497.42 | 5,637,579.03 | 3,663,805.56 |
| 其中:利息收入 | 2,665,455.16 | 20,212,474.49 | 17,798,319.46 | 15,767,480.85 |
| 加:公允价值变动收益 | 806,582.36 | 5,499,523.61 | 245,185.77 | -285,309.56 |
| 加:投资收益 | 5,833,292.85 | 22,864,552.69 | 11,517,089.34 | 3,435,600.31 |
| 资产减值损失(新) | - | -9,406,759.08 | -1,565,541.4 | -1,565,541.4 |
| 信用减值损失(新) | -9,065,194.99 | -7,260,983.68 | -9,984,056.64 | -9,607,429.03 |
| 其他收益 | 2,408,407.73 | 9,639,276.44 | 8,142,425.6 | 6,292,741.82 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 136,769,869.82 | 241,143,575.95 | 261,919,470.22 | 208,115,873.58 |
| 加:营业外收入 | 260,841.91 | 1,360.78 | 360.78 | 360.28 |
| 减:营业外支出 | 298,244.4 | 944,888.08 | 640,343.61 | 547,279.97 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 136,732,467.33 | 240,200,048.65 | 261,279,487.39 | 207,568,953.89 |
| 减:所得税费用 | 17,533,278.56 | 33,409,031.43 | 32,293,813.73 | 27,736,559.65 |
| 六、净利润 | 119,199,188.77 | 206,791,017.22 | 228,985,673.66 | 179,832,394.24 |
| 持续经营净利润 | 119,199,188.77 | 206,791,017.22 | 228,985,673.66 | 179,832,394.24 |
| 归属于母公司股东的净利润 | 119,199,188.77 | 206,791,017.22 | 228,985,673.66 | 179,832,394.24 |
| (一)基本每股收益 | 0.14 | 0.25 | 0.28 | 0.22 |
| (二)稀释每股收益 | 0.14 | 0.25 | 0.28 | 0.22 |
| 八、其他综合收益 | 670,246.53 | 29,582.57 | 7,367.73 | 15,617.25 |
| 归属于母公司股东的其他综合收益 | 670,246.53 | 29,582.57 | 7,367.73 | 15,617.25 |
| 九、综合收益总额 | 119,869,435.3 | 206,820,599.79 | 228,993,041.39 | 179,848,011.49 |
| 归属于母公司股东的综合收益总额 | 119,869,435.3 | 206,820,599.79 | 228,993,041.39 | 179,848,011.49 |
| 公告日期 | 2025-04-30 | 2025-04-30 | 2024-10-30 | 2024-08-24 |
| 审计意见(境内) | | 标准无保留意见 | | |